Traws Pharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.8M | $226,000 | $226,000 | $226,000 | $226,000 |
| Research and development | $12.1M | $12.8M | $11.4M | $11.4M | $7.3M |
| Operating expenses | $20.7M | $142.6M | $20.5M | $19.9M | $16.7M |
| Operating income | -$17.9M | -$142.4M | -$20.3M | -$19.6M | -$16.5M |
| Pretax income | $9.2M | -$166.5M | -$18.9M | -$19.0M | -$16.2M |
| Net income | $9.2M | -$166.5M | -$18.9M | -$19.0M | -$16.2M |
| Balance Sheet | |||||
| Cash and equivalents | — | — | $20.6M | $38.5M | — |
| Current assets | $8.0M | $25.0M | $22.7M | $39.3M | $55.4M |
| Total assets | $10.6M | $25.0M | $22.7M | $39.4M | $55.5M |
| Current liabilities | $11.1M | $11.5M | $9.2M | $8.0M | $6.1M |
| Total liabilities | $11.2M | $56.6M | $12.0M | $11.1M | $9.4M |
| Stockholders' equity | -$629,000 | -$31.6M | $10.7M | $28.3M | $46.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$18.2M | -$29.8M | -$17.9M | -$16.3M | -$19.5M |
| Depreciation and amortization | $61,000 | $12,000 | $16,000 | $14,000 | $14,000 |
| Stock-based compensation | $728,000 | $1.4M | $1.3M | $1.2M | $576,000 |
| Capital expenditure | $2.6M | $3.6M | $14,000 | — | — |
| Free cash flow | -$20.8M | -$33.4M | -$17.9M | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 15.2M · Free float 6.4%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.